Neil Powe, MD, MPH, MBA

Professor

Dr. Powe serves as leader of the University of California San Francisco Medicine Service at the Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, a leading Medicine department in a public hospital with strong basic, clinical and health services research programs focused on major diseases affecting diverse patients locally, nationally and globally. His interests are in improving discovery, education and clinical practice in medicine, making academic organizations function better, enhancing scholarship and multidisciplinary collaboration, and developing future talent and leadership in the health professions. He has a particular interest in cultivating young scientists who are addressing major problems in science, health and health care delivery.

His primary intellectual pursuits involve kidney disease patient-oriented research, epidemiology and outcomes and effectiveness research. His research unites Medicine and Public Health with the goals of saving and improving quality of human lives. It involves the knowledge of fundamental discoveries in biology and clinical medicine to advance the health of patients and populations affected by kidney disease.

Dr. Powe earned his medical degree at Harvard Medical School and his master’s in public health at Harvard School of Public Health. He completed residency, was a Robert Wood Johnson Clinical Scholar and completed his master’s in business administration at the University of Pennsylvania.
Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Honors and Awards
  • David M. Hume Memorial Award, National Kidney Foundation, 2019
  • Fellow, American Association for the Advancement of Science, 2017
  • Belding H. Scribner Award, American Society of Nephrology, 2011
  • Master, American College of Physicians, 2010
  • Diversity Award, Association of Professors of Medicine, 2010
  • Champion of Hope Award, National Kidney Foundation, 2008
  • Distinguished Educator Award, Association for Clinical Research Training, 2007
  • Member, Association of American Physicians, 2005
  • John M. Eisenberg National Award for Career Achievement in Research, Society of General Internal Medicine, 2005
  • Garabed Eknoyan Award, National Kidney Foundation, 2004
  • Member, National Academy of Medicine, 2003
  • Member, American Society of Clinical Investigation, 2000
  • Teaching and Research Scholar, American College of Physicians, 1989
Websites
Publications
  1. Improving Access to Kidney Transplantation: Business as Usual or New Ways of Doing Business?
  2. The relation between dialysis-requiring acute kidney injury and recovery from end-stage renal disease: a national study.
  3. Trends in Quality of Care for Patients with CKD in the United States.
  4. The Status of Provision of Standard Outpatient Dialysis for US Undocumented Immigrants with ESKD.
  5. Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.
  6. Elevated serum anion gap in adults with moderate chronic kidney disease increases risk for progression to end-stage renal disease.
  7. Contribution of 'clinically negligible' residual kidney function to clearance of uremic solutes.
  8. CKD Progression: Teasing Out Contributions of Elements in the Human Exposome.
  9. Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension.
  10. Low use of routine medical care among African Americans with high CKD risk: the Jackson Heart Study.
  11. Vascular Calcification Markers and Hemodialysis Vascular Access Complications.
  12. Association between health literacy and self-care behaviors among patients with chronic kidney disease.
  13. County-level air quality and the prevalence of diagnosed chronic kidney disease in the US Medicare population.
  14. Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study.
  15. Dietary Potential Renal Acid Load and Risk of Albuminuria and Reduced Kidney Function in the Jackson Heart Study.
  16. Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients.
  17. Acid Balance, Dietary Acid Load, and Bone Effects-A Controversial Subject.
  18. Race/Ethnicity, Dietary Acid Load, and Risk of End-Stage Renal Disease among US Adults with Chronic Kidney Disease.
  19. Acceptability of a multilevel intervention to improve blood pressure control among patients with chronic kidney disease in a public health care delivery system.
  20. Closing the gap between evidence and practice in chronic kidney disease.
  21. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.
  22. Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
  23. Recent trends in the prevalence of chronic kidney disease: not the same old song.
  24. Colon Cancer Screening among Patients Receiving Dialysis in the United States: Are We Choosing Wisely?
  25. Food Insecurity, CKD, and Subsequent ESRD in US Adults.
  26. Free and total p-cresol sulfate levels and infectious hospitalizations in hemodialysis patients in CHOICE and HEMO.
  27. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
  28. Dietary Habits and Risk of Kidney Function Decline in an Urban Population.
  29. Trends in Prevalence of Chronic Kidney Disease in the United States.
  30. Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients.
  31. Health-Related Quality of Life in CKD-Advancing Patient-Centered Research to Transform Patient Care.
  32. Dietary Salt, Kidney Disease, and Cardiovascular Health.
  33. Racial Disparities in Creatinine-based Kidney Function Estimates Among HIV-infected Adults.
  34. Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS).
  35. Adolescent Perceptions of Outgrowing Childhood Attention-Deficit Hyperactivity Disorder: Relationship to Symptoms and Quality of Life.
  36. Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study.
  37. Association of NTproBNP and cTnI with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study.
  38. Exploring Potential Reasons for the Temporal Trend in Dialysis-Requiring AKI in the United States.
  39. Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled.
  40. Acute Kidney Injury Recovery Pattern and Subsequent Risk of CKD: An Analysis of Veterans Health Administration Data.
  41. Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA.
  42. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 27-2015. A 78-Year-Old Man with Hypercalcemia and Renal Failure.
  43. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
  44. CKD as a Model for Improving Chronic Disease Care through Electronic Health Records.
  45. Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators.
  46. 24,25-Dihydroxyvitamin d3 and vitamin D status of community-dwelling black and white Americans.
  47. High Dietary Acid Load Predicts ESRD among Adults with CKD.
  48. Low income, community poverty and risk of end stage renal disease.
  49. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans.
  50. Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.
  51. Dietary habits, poverty, and chronic kidney disease in an urban population.
  52. Variation in structure and delivery of care between kidney transplant centers in the United States.
  53. Dietary acid load and chronic kidney disease among adults in the United States.
  54. Taming the chronic kidney disease epidemic: a global view of surveillance efforts.
  55. An instrumental variable approach finds no associated harm or benefit with early dialysis initiation in the United States.
  56. Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study.
  57. Biomarkers of vascular calcification and mortality in patients with ESRD.
  58. Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
  59. Predialysis health, dialysis timing, and outcomes among older United States adults.
  60. Socioeconomic factors and racial disparities in kidney disease outcomes.
  61. Measuring and explaining racial and ethnic differences in willingness to donate live kidneys in the United States.
  62. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators.
  63. The effect of depression symptoms and social support on black-white differences in health-related quality of life in early pregnancy: the health status in pregnancy (HIP) study.
  64. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review.
  65. Estimating prevalence of CKD stages 3-5 using health system data.
  66. Association between adiponectin and tumor necrosis factor-alpha levels at eight to fourteen weeks gestation and maternal glucose tolerance: the Parity, Inflammation, and Diabetes Study.
  67. Selecting renal replacement therapies: what do African American and non-African American patients and their families think others should know? A mixed methods study.
  68. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients.
  69. Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study.
  70. Development of a decision aid to inform patients' and families' renal replacement therapy selection decisions.
  71. Iliac vein compression as risk factor for left- versus right-sided deep venous thrombosis: case-control study.
  72. Effectiveness of educational and social worker interventions to activate patients' discussion and pursuit of preemptive living donor kidney transplantation: a randomized controlled trial.
  73. The providing resources to enhance African American patients' readiness to make decisions about kidney disease (PREPARED) study: protocol of a randomized controlled trial.
  74. Solid-organ transplantation in older adults: current status and future research.
  75. African American and non-African American patients' and families' decision making about renal replacement therapies.
  76. Serum ß-trace protein and risk of mortality in incident hemodialysis patients.
  77. Low income and albuminuria among REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants.
  78. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies.
  79. Willingness of the United States general public to participate in kidney paired donation.
  80. Inflammation and the paradox of racial differences in dialysis survival.
  81. Genetic variation in APOL1 associates with younger age at hemodialysis initiation.
  82. Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD.
  83. Association between hospitals caring for a disproportionately high percentage of minority trauma patients and increased mortality: a nationwide analysis of 434 hospitals.
  84. Patient-physician social concordance, medical visit communication and patients' perceptions of health care quality.
  85. Association of sleep-related problems with CKD in the United States, 2005-2008.
  86. Donor designation: racial and ethnic differences in US nondesignators' preferred methods for disclosing intent to donate organs.
  87. Protocol of a randomized controlled trial of culturally sensitive interventions to improve African Americans' and non-African Americans' early, shared, and informed consideration of live kidney transplantation: the Talking About Live Kidney Donation (TALK
  88. Identifying and addressing barriers to African American and non-African American families' discussions about preemptive living related kidney transplantation.
  89. Inflammatory markers and risk of cerebrovascular events in patients initiating dialysis.
  90. World Kidney Day 2011.
  91. Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients.
  92. Effect of primary care physicians' use of estimated glomerular filtration rate on the timing of their subspecialty referral decisions.
  93. Primary care-specialist collaboration in the care of patients with chronic kidney disease.
  94. Do minority patients use lower quality hospitals?
  95. Quality of patient-physician discussions about CKD in primary care: a cross-sectional study.
  96. Association of CKD with disability in the United States.
  97. Blood pressure and mortality among ESRD patients: all patients are not created equal.
  98. Race, ethnicity, and shared decision making for hyperlipidemia and hypertension treatment: the DECISIONS survey.
  99. Validation of CKD and related conditions in existing data sets: A systematic review.
  100. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.
  101. Uterine artery embolization versus abdominal myomectomy: a long-term clinical outcome comparison.
  102. Association of social support with outcomes in incident dialysis patients.
  103. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes.
  104. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States.
  105. Poverty, race, and CKD in a racially and socioeconomically diverse urban population.
  106. The association of provider communication with trust among adults with sickle cell disease.
  107. Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status.
  108. Establishing a national chronic kidney disease surveillance system for the United States.
  109. 25-hydroxyvitamin D levels, race, and the progression of kidney disease.
  110. The effects of a nurse case manager and a community health worker team on diabetic control, emergency department visits, and hospitalizations among urban African Americans with type 2 diabetes mellitus: a randomized controlled trial.
  111. Impact of Medicare coverage on disparities in access to simultaneous pancreas and kidney transplantation.
  112. Inpatient hemodialysis initiation: reasons, risk factors and outcomes.
  113. Correlates and outcomes of fatigue among incident dialysis patients.
  114. Effect of hospital setting and volume on clinical outcomes in women with gestational and type 2 diabetes mellitus.
  115. Longitudinal study of depressive symptoms and health-related quality of life during pregnancy and after delivery: the Health Status in Pregnancy (HIP) study.
  116. Perceived susceptibility to chronic kidney disease among high-risk patients seen in primary care practices.
  117. Peripheral vascular disease-related procedures in dialysis patients: predictors and prognosis.
  118. External validity of the cardiovascular health study: a comparison with the Medicare population.
  119. Considerations in the statistical analysis of hemodialysis patient survival.
  120. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006.
  121. Association of peritoneal dialysis clinic size with clinical outcomes.
  122. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study.
  123. Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians.
  124. Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients.
  125. Introduction to the Proceedings of a Centers for Disease Control and Prevention Expert Panel Workshop: developing a comprehensive public health strategy for preventing the development, progression, and complications of CKD.
  126. Population-based screening for CKD.
  127. Public health surveillance of CKD: principles, steps, and challenges.
  128. World Kidney Day 2009: problems and challenges in the emerging epidemic of kidney disease.
  129. Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: development of a scale.
  130. Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study.
  131. Clinical information technologies and inpatient outcomes: a multiple hospital study.
  132. Personal physicians as study investigators: impact on patients' willingness to participate in clinical trials.
  133. Age and comorbidities are effect modifiers of gender disparities in renal transplantation.
  134. Improving the diversity climate in academic medicine: faculty perceptions as a catalyst for institutional change.
  135. Patient awareness of chronic kidney disease: trends and predictors.
  136. Hospital characteristics associated with highly automated and usable clinical information systems in Texas, United States.
  137. MYH9 is associated with nondiabetic end-stage renal disease in African Americans.
  138. The association of sudden cardiac death with inflammation and other traditional risk factors.
  139. Postdischarge environmental and socioeconomic factors and the likelihood of early hospital readmission among community-dwelling Medicare beneficiaries.
  140. Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important.
  141. Phosphate levels and blood pressure in incident hemodialysis patients: a longitudinal study.
  142. The association of state and national legislation with living kidney donation rates in the United States: a national study.
  143. Serum phosphate levels and risk of infection in incident dialysis patients.
  144. Let's get serious about racial and ethnic disparities.
  145. Impact of activated vitamin D and race on survival among hemodialysis patients.
  146. Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD.
  147. Do hospitals provide lower-quality care to minorities than to whites?
  148. Correction: Inaccurate classification and information reported in a study of statin use and sepsis in patients with chronic kidney disease.
  149. World Kidney Day 2008: think globally, speak locally.
  150. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.
  151. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials.
  152. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study.
  153. Principles of screening for chronic kidney disease.
  154. Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection.
  155. Comorbidity and outcomes of coronary artery bypass graft surgery at cardiac specialty hospitals versus general hospitals.
  156. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
  157. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients.
  158. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
  159. Weight loss programs for urban-based, postpartum African-American women: perceived barriers and preferred components.
  160. Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study.
  161. Perceived transparency and fairness of the organ allocation system and willingness to donate organs: a national study.
  162. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials.
  163. Individual and neighborhood socioeconomic status and progressive chronic kidney disease in an elderly population: The Cardiovascular Health Study.
  164. Statin use and sepsis events [corrected] in patients with chronic kidney disease.
  165. Preferences for current health and their association with outcomes in patients with kidney disease.
  166. Measuring clinical information technology in the ICU setting: application in a quality improvement collaborative.
  167. Systematic review: the value of the periodic health evaluation.
  168. Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis.
  169. Provider roles in the recruitment of underrepresented populations to cancer clinical trials.
  170. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study.
  171. Applying justice in clinical trials for diverse populations.
  172. Increased risk of type 2 diabetes from a family history of coronary heart disease and type 2 diabetes.
  173. Schizophrenia, AIDS and the decision to prescribe HAART: results of a national survey of HIV clinicians.
  174. Self-administered instruments to measure cultural competence of health professionals: a systematic review.
  175. Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients.
  176. Parity and risk of type 2 diabetes: the Atherosclerosis Risk in Communities Study.
  177. The economics and ethics of kidney transplantation: perspectives in 2006.
  178. Public attitudes toward incentives for organ donation: a national study of different racial/ethnic and income groups.
  179. Maternal race, procedures, and infant birth weight in type 2 and gestational diabetes.
  180. Reverse race and ethnic disparities in survival increase with severity of chronic kidney disease: what does this mean?
  181. Association of clinic vascular access monitoring practices with clinical outcomes in hemodialysis patients.
  182. Identification and referral of patients with progressive CKD: a national study.
  183. Self-perceived loss of control and untreated dental decay in African American adults with and without sickle cell disease.
  184. Prevalence of immune thrombocytopenia: analyses of administrative data.
  185. Haplotype of signal transducer and activator of transcription 3 gene predicts cardiovascular disease in dialysis patients.
  186. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk.
  187. Sleep quality and its correlates in the first year of dialysis.
  188. Prevalence of postpartum thyroid dysfunction: a quantitative review.
  189. Use and costs of nonrecommended tests during routine preventive health exams.
  190. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.
  191. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study.
  192. The association between sickle cell disease and dental caries in African Americans.
  193. Improving health care quality for racial/ethnic minorities: a systematic review of the best evidence regarding provider and organization interventions.
  194. Depressive symptoms and health-related quality of life in early pregnancy.
  195. Value of the periodic health evaluation.
  196. Defining "success" in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach.
  197. Are development times for pharmaceuticals increasing or decreasing?
  198. Clinical information technology capabilities in four U.S. hospitals: testing a new structural performance measure.
  199. Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: contribution of reverse causality.
  200. Association of social problem solving with glycemic control in a sample of urban African Americans with type 2 diabetes.
  201. Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials.
  202. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients.
  203. The association between women's health information use and health care visits.
  204. Use of dialysis educators beyond nurses and physicians and outcomes in patients with kidney failure.
  205. Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities.
  206. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease.
  207. Area socioeconomic status and progressive CKD: the Atherosclerosis Risk in Communities (ARIC) Study.
  208. Do drug prices reflect development time and government investment?
  209. Attitudes, psychology, and risk taking of potential live kidney donors: strangers, relatives, and the general public.
  210. The role of cultural diversity climate in recruitment, promotion, and retention of faculty in academic medicine.
  211. American Society of Pediatric Nephrology position paper on linking reimbursement to quality of care.
  212. Report of the National Heart, Lung, and Blood Institute working group on outcomes research in cardiovascular disease.
  213. A systematic review of the methodological rigor of studies evaluating cultural competence training of health professionals.
  214. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials.
  215. Preferences, knowledge, communication and patient-physician discussion of living kidney transplantation in African American families.
  216. Screening for gestational diabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies.
  217. Racial disparities in the optimal delivery of chronic kidney disease care.
  218. Cultural competence: a systematic review of health care provider educational interventions.
  219. Extent and determinants of physician participation in expert witness testimony.
  220. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
  221. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study.
  222. Frequency of patient-physician contact in chronic kidney disease care and achievement of clinical performance targets.
  223. Association between screening for osteoporosis and the incidence of hip fracture.
  224. Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients.
  225. Patient race/ethnicity and quality of patient-physician communication during medical visits.
  226. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Surve
  227. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures.
  228. Barriers to health care access among the elderly and who perceives them.
  229. How strong are patients' preferences in choices between dialysis modalities and doses?
  230. Whole body donation for medical science: a population-based study.
  231. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.
  232. Diversifying the racial and ethnic composition of the physician workforce.
  233. The impact of international medical graduate status on primary care physicians' choice of specialist.
  234. Referral of patients to specialists: factors affecting choice of specialist by primary care physicians.
  235. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival.
  236. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients.
  237. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition.
  238. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures.
  239. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis.
  240. A randomized controlled trial of the effects of nurse case manager and community health worker team interventions in urban African-Americans with type 2 diabetes.
  241. Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments.
  242. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients.
  243. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.
  244. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study.
  245. Frequency of patient-physician contact and patient outcomes in hemodialysis care.
  246. Prenatal patients' views of prenatal care services: a medical center-based assessment of knowledge and intent to use support services.
  247. Strategies for improving minority healthcare quality.
  248. Screening for proteinuria in US adults: a cost-effectiveness analysis.
  249. Patient-centered communication, ratings of care, and concordance of patient and physician race.
  250. Clinical management of primary hyperparathyroidism and thresholds for surgical referral: a national study examining concordance between practice patterns and consensus panel recommendations.
  251. Predictors of cause-specific hospital readmission in patients with heart failure.
  252. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults.
  253. Receipt of renal replacement therapy in the United States: a population-based study of sociodemographic disparities from the Second National Health and Nutrition Examination Survey (NHANES II).
  254. To have and have not: Health and health care disparities in chronic kidney disease.
  255. Cardiac Resynchronization for Progressive Heart Failure-Reply.
  256. Lifestyle factors, obesity and the risk of chronic kidney disease.
  257. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study.
  258. Race and trust in the health care system.
  259. Use of glycated hemoglobin and microalbuminuria in the monitoring of diabetes mellitus.
  260. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease.
  261. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.
  262. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials.
  263. Early referral in chronic kidney disease: an enormous opportunity for prevention.
  264. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States.
  265. The relationship of race to women's use of health information resources.
  266. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
  267. Comorbidity and its change predict survival in incident dialysis patients.
  268. Effects of patient compliance, parental education and race on nephrologists' recommendations for kidney transplantation in children.
  269. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study.
  270. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study.
  271. Characteristics of primary care visits for individuals with severe mental illness in a national sample.
  272. Utility of blood pressure monitoring outside of the clinic setting.
  273. The uneven distribution of kidney transplants: getting at the root causes and improving care.
  274. The timing of specialist evaluation in chronic kidney disease and mortality.
  275. Development and use of evidence-based clinical practice guidelines for thyroid disease.
  276. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors.
  277. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.
  278. Designing and evaluating interventions to eliminate racial and ethnic disparities in health care.
  279. Growth failure, risk of hospitalization and death for children with end-stage renal disease.
  280. The contribution of sociodemographic, medical, and attitudinal factors to blood donation among the general public.
  281. Determinants of willingness to donate living related and cadaveric organs: identifying opportunities for intervention.
  282. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study.
  283. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes.
  284. Quality of clinical reports on behavioral interventions for hypertension.
  285. Is health plan employer data and information set performance associated with withdrawal from medicare managed care?
  286. Race-specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients: the CHOICE Study.
  287. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease.
  288. The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologists.
  289. The general public's concerns about clinical risk in live kidney donation.
  290. Understanding disparities in donor behavior: race and gender differences in willingness to donate blood and cadaveric organs.
  291. Weight-modification trials in older adults: what should the outcome measure be?
  292. Cost-quality trade-offs in dialysis care: a national survey of dialysis facility administrators.
  293. Geographic socioeconomic status, race, and advanced-stage breast cancer in New York City.
  294. Autologous blood transfusion in the United States: clinical and nonclinical determinants of use.
  295. The impact of practice guidelines in the management of Barrett esophagus: a national prospective cohort study of physicians.
  296. Evidence-based practice centers: production of evidence report on management of atrial fibrillation.
  297. Incidence and predictors of coronary heart disease among older African Americans--the Cardiovascular Health Study.
  298. An evidence-based review of patient-centered behavioral interventions for hypertension.
  299. Does growth retardation indicate suboptimal clinical care in children with chronic renal disease and those undergoing dialysis?
  300. How important is intrinsic spirituality in depression care? A comparison of white and African-American primary care patients.
  301. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.
  302. Factors influencing access to cardiovascular procedures in patients with chronic kidney disease: race, sex, and insurance.
  303. Income-based disparities in outcomes for patients with chronic kidney disease.
  304. Primary care physician job satisfaction and turnover.
  305. Profit-making in the treatment of chronic kidney disease: truth and consequences.
  306. Reducing racial disparities in transplant activation: whom should we target?
  307. Thrombolytic therapy and mortality.
  308. Validating billing data for RBC transfusions: a brief report.
  309. Patterns of ambulatory care use for gynecologic conditions: A national study.
  310. Specialty of principal care physician and Medicare expenditures in patients with coronary artery disease: impact of comorbidity and severity.
  311. Relation between pediatric experience and treatment recommendations for children and adolescents with kidney failure.
  312. U.S. nephrologists' attitudes towards renal transplantation: results from a national survey.
  313. A computerized tool for evaluating the effectiveness of preventive interventions.
  314. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
  315. Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire.
  316. Managed care and primary care physicians' overall career satisfaction.
  317. Medical care: past, present, and future.
  318. Patients, populations and policy: patient outcomes in chronic kidney disease.
  319. Quality of care at teaching and nonteaching hospitals.
  320. Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy.
  321. Relation between gender and vascular access complications in hemodialysis patients.
  322. US nephrologists' recommendation of dialysis modality: results of a national survey.
  323. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials.
  324. Prescription drugs in Medicare and the ESRD program.
  325. Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease.
  326. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.
  327. Cost-utility analysis of the cochlear implant in children.
  328. Formal literature review of quality-of-life instruments used in end-stage renal disease.
  329. Barriers pediatricians face when using asthma practice guidelines.
  330. Economic burden of hospitalizations for preterm labor in the United States.
  331. Race- and sex-specific ECG models for left ventricular mass in older populations. Factors influencing overestimation of left ventricular hypertrophy prevalence by ECG criteria in African-Americans.
  332. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years.
  333. Impact of gender on access to the renal transplant waiting list for pediatric and adult patients.
  334. Management of new onset atrial fibrillation.
  335. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus.
  336. Primary care patients' opinions regarding the importance of various aspects of care for depression.
  337. Evaluation of common problems in primary care: effects of physician, practice, and financial characteristics.
  338. Relation of gender and health insurance to cardiovascular procedure use in persons with progression of chronic renal disease.
  339. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD.
  340. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients.
  341. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.
  342. The evidence regarding the drugs used for ventricular rate control.
  343. The role of peer-reviewed journals in science.
  344. Factors affecting prophylactic oophorectomy in postmenopausal women.
  345. Management of Barrett's esophagus: a national study of practice patterns and their cost implications.
  346. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation.
  347. Estimates of costs of primary care physician turnover.
  348. Why don't physicians follow clinical practice guidelines? A framework for improvement.
  349. Medicare expenditures for beneficiaries with dementia of the Alzheimer's type.
  350. Mental health service utilization by African Americans and Whites: the Baltimore Epidemiologic Catchment Area Follow-Up.
  351. Predicting expenditures for Medicare beneficiaries with diabetes. A prospective cohort study from 1994 to 1996.
  352. For-profit versus not-for-profit dialysis care for children with end stage renal disease.
  353. Race, gender, and partnership in the patient-physician relationship.
  354. To cover or not to cover: how to decide?
  355. Use of focus groups to identify concerns about dialysis. Choice Study.
  356. The relation between funding by the National Institutes of Health and the burden of disease.
  357. The association between hospital volume and survival after acute myocardial infarction in elderly patients.
  358. Methodological hurdles in conducting pharmacoeconomic analyses.
  359. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group.
  360. Septicemia in dialysis patients: incidence, risk factors, and prognosis.
  361. Use of cardiovascular procedures among black persons and white persons: a 7-year nationwide study in patients with renal disease.
  362. Cost implications of different surgical management strategies for primary hyperparathyroidism.
  363. Capitation for cardiologists: accepting risk for coronary artery disease under managed care.
  364. Atrial fibrillation: mortality, stroke, and medical costs.
  365. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy.
  366. Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons.
  367. "Carving out" conditions from global capitation rates: protecting high-cost patients, physicians, and health plans in a managed care environment.
  368. Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns.
  369. Factors Associated With Hospital Utilization in the Elderly: From the Cardiovascular Health Study.
  370. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care.
  371. Patient's view of dialysis care: development of a taxonomy and rating of importance of different aspects of care. CHOICE study. Choices for Healthy Outcomes in Caring for ESRD.
  372. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis.
  373. Identification of patient attitudes and preferences regarding treatment of depression.
  374. Does greater pediatric experience influence treatment choices in chronic disease management? Dialysis modality choice for children with end-stage renal disease.
  375. Technology coverage decisions by health care plans and considerations by medical directors.
  376. Racial differences in choice of dialysis modality for children with end-stage renal disease.
  377. Decision analysis in endocrinology and metabolism.
  378. Systemwide provider performance in a Medicaid program. Profiling the care of patients with chronic illnesses.
  379. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.
  380. Quality assessment: is the focus on providers or on patients?
  381. Measuring effectiveness and outcomes of interventions for renal disease.
  382. The review process used by US health care plans to evaluate new medical technology for coverage.
  383. Ambulatory care practice variation within a Medicaid program.
  384. Awareness of providers' use of new medical technology among private health care plans in the United States.
  385. Screening for dialysis access graft malfunction: comparison of physical examination with US.
  386. The role of perspective in defining economic measures for the evaluation of medical technology.
  387. The clinical-economic trial: promise, problems, and challenges.
  388. Black-white differences in subclinical cardiovascular disease among older adults: the Cardiovascular Health Study. CHS Collaborative Research Group.
  389. Hematological and biochemical laboratory values in older Cardiovascular Health Study participants.
  390. Small area variations in health care delivery in Maryland.
  391. Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial.
  392. A survey of current problems in meta-analysis. Discussion from the Agency for Health Care Policy and Research inter-PORT Work Group on Literature Review/Meta-Analysis.
  393. Cost-effectiveness analyses.
  394. Costs vs quality in different types of primary care settings.
  395. Simulated lifetime costs of three types of employer-based, periodic, breast cancer screening programs for working-age women.
  396. The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities.
  397. Measuring, managing, and improving quality in the end-stage renal disease treatment setting: committee statement.
  398. Alternative methods for formal literature review and meta-analysis in AHCPR Patient Outcomes Research Teams. Agency for Health Care Policy and Research.
  399. Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs.
  400. Economic and cost-effectiveness investigations of radiologic practices.
  401. Rigor of research methods in studies of the effectiveness and safety of cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team.
  402. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team.
  403. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients.
  404. A review of the first year of Medicare coverage of erythropoietin.
  405. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
  406. The cost of ethics legislation: a look at the Patient Self-Determination Act.
  407. Adverse reactions to contrast media: factors that determine the cost of treatment.
  408. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
  409. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
  410. Facts and fears regarding blood transfusions in decision making for thrombolytic therapy.
  411. Factors influencing third party payer costs for allogeneic BMT.
  412. Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography.
  413. Early dosing practices and effectiveness of recombinant human erythropoietin.
  414. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
  415. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
  416. Low-versus high-osmolality contrast media for intravenous use: a health care luxury or necessity?
  417. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial.
  418. Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography.
  419. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis.
  420. Nephrotoxicity of low osmolality contrast media versus high osmolality media.
  421. The effects of intracoronary contrast in the denervated human heart.
  422. Controlled trials of radiologic contrast media: issues in quality assessment and synthesis.
  423. Applying insurance claims data to assess quality of care: a compilation of potential indicators.
  424. Variations in cataract management: patient and economic outcomes.
  425. Risk reduction from low osmolality contrast media. What do patients think it is worth?
  426. Development of clinical and economic prognoses from Medicare claims data.
  427. Setting payment rates for capitated systems: a comparison of various alternatives.
  428. Frequency and determinants of adverse reactions induced by high-osmolality contrast media.
  429. Quality assessment of randomized controlled trials of contrast media.
  430. Results of randomized controlled trials of low-versus high-osmolality contrast media.
  431. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction.
  432. Contrast medium-induced adverse reactions: economic outcome.
  433. Payment reform's impact on quality of hospital products.
  434. Use of low-osmolality contrast media in a price-sensitive environment.
  435. Reducing the cost of using contrast media: a look at discarded volumes.
  436. Learning to keep the gate open to needed medical care.
  437. "Gatekeeper technology." Recasting a primary care role.
  438. Health care for black Americans: the public sector role.
  439. Studying and teaching the gatekeeper.